Remimazolam Besylate in Sedation of Postcardioperative Patients

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

April 30, 2025

Study Completion Date

May 31, 2025

Conditions
RemimazolamPropofolSedationMechanical VentilationIntensive CareCardiac Surgery
Interventions
DRUG

Remimazolam

participants in the remimazolam group received remimazolam besylate intravenously at an initial infusion rate of 0.2mg/kg/h and adjusted (maximum of 2 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale(RASS) score between - 2 and 0.If the maximum dose of remimazolam was insufficient to sedate, add rescue dexmedetomidine.

DRUG

Propofol

participants in the propofol group received propofol intravenously at an initial infusion rate of 1 mg/kg/h and adjusted (maximum of 4 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale (RASS) score between - 2 and 0.If the maximum dose of propofol was insufficient to sedate, add rescue dexmedetomidine.

Trial Locations (1)

310000

RECRUITING

First afflilated hospital of zhejiang university school of medicine, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER